Despite FDA CAR-T Probe, AstraZeneca Pursues Cell Therapy with Gracell Deal
The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies,…